Q-omics provides the consensus-scored SF3A1 profile across patient tissues and cancer cell-line models. SF3A1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SF3A1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, SF3A1 protein abundance shows 33,070 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where SF3A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SF3A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SF3A1 survival associations across molecular data types. SF3A1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SF3A1 RNA expression–survival associations across cancer types. High SF3A1 expression shows unfavorable associations in ACC, MESO and LIHC, but favorable associations in KIRC, LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SF3A1 RNA expression.
This table summarizes SF3A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SF3A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SF3A1 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, CHOL and STAD. The LIHC box plot shows higher SF3A1 RNA expression in tumor versus normal tissue (log2 FC = +1.144, t-test p < 0.001).
This table shows molecular features associated with SF3A1 in patient tissues and cancer cell lines. In patient samples, SF3A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SF3A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
